|
DE1073471B
(de)
|
1958-09-02 |
1960-01-21 |
Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) |
Verfahren zur Herstellung von Azelainsäure
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US5422120A
(en)
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
WO1990007936A1
(en)
|
1989-01-23 |
1990-07-26 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
|
US5583160A
(en)
|
1989-02-03 |
1996-12-10 |
The Biomembrane Institute |
Methylsphingosine used to treat apoptosis
|
|
US6673776B1
(en)
|
1989-03-21 |
2004-01-06 |
Vical Incorporated |
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
CA2489769A1
(en)
|
1989-03-21 |
1990-10-04 |
Philip L. Felgner |
Expression of exogenous polynucleotide sequences in a vertebrate
|
|
AU648261B2
(en)
|
1989-08-18 |
1994-04-21 |
Novartis Vaccines And Diagnostics, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
ZA911974B
(en)
|
1990-03-21 |
1994-08-22 |
Res Dev Foundation |
Heterovesicular liposomes
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US5137919A
(en)
|
1990-12-31 |
1992-08-11 |
Biomembrane Institute |
Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation
|
|
US5466716A
(en)
|
1990-12-31 |
1995-11-14 |
The Biomembrane Institute |
Liposomal trimethylsphingosine
|
|
US5248824A
(en)
|
1990-12-31 |
1993-09-28 |
The Biomembrane Institute |
Method of preparing N,N,N-trimethylsphingosine
|
|
US5151360A
(en)
|
1990-12-31 |
1992-09-29 |
Biomembrane Institute |
Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5260288A
(en)
|
1992-04-03 |
1993-11-09 |
The Biomembrane Institute |
Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
|
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
|
CA2137361A1
(en)
|
1992-06-10 |
1993-12-23 |
W. French Anderson |
Vector particles resistant to inactivation by human serum
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
US6210671B1
(en)
|
1992-12-01 |
2001-04-03 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with L-selectin
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
PT695169E
(pt)
|
1993-04-22 |
2003-04-30 |
Skyepharma Inc |
Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
|
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
US6015686A
(en)
|
1993-09-15 |
2000-01-18 |
Chiron Viagene, Inc. |
Eukaryotic layered vector initiation systems
|
|
DK0814154T3
(da)
|
1993-09-15 |
2009-08-31 |
Novartis Vaccines & Diagnostic |
Rekombinante alfavirusvektorer
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
AU686277B2
(en)
|
1993-11-16 |
1998-02-05 |
Pacira Pharmaceuticals, Inc. |
Vesicles with controlled release of actives
|
|
US5627171A
(en)
|
1994-04-11 |
1997-05-06 |
Oncomembrane, Inc. |
Sphingosine-1-phosphate/trimethylsphingosine composition
|
|
US6436908B1
(en)
|
1995-05-30 |
2002-08-20 |
Duke University |
Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
|
|
DE69535669T2
(de)
|
1994-05-09 |
2008-12-04 |
Oxford Biomedica (Uk) Ltd. |
Retrovirale vektoren mit verminderter rekombinationsrate
|
|
AU4594996A
(en)
|
1994-11-30 |
1996-06-19 |
Chiron Viagene, Inc. |
Recombinant alphavirus vectors
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
WO1997042338A1
(en)
|
1996-05-06 |
1997-11-13 |
Chiron Corporation |
Crossless retroviral vectors
|
|
GB9616105D0
(en)
|
1996-07-31 |
1996-09-11 |
Univ Kingston |
TrkA binding site of NGF
|
|
US6649362B2
(en)
|
1997-09-08 |
2003-11-18 |
Medvet Science Pty. Ltd. |
Screening method for an agent having an effect on a sphingosine kinase signaling pathway
|
|
AUPO900297A0
(en)
|
1997-09-08 |
1997-10-02 |
Medvet Science Pty. Ltd. |
A method of modulating cellular activity
|
|
US6376471B1
(en)
|
1997-10-10 |
2002-04-23 |
Johns Hopkins University |
Gene delivery compositions and methods
|
|
US6098631A
(en)
*
|
1998-01-21 |
2000-08-08 |
The Regents Of The University Of Michigan |
Compositions and methods for treating autoimmune disease
|
|
US6849425B1
(en)
|
1999-10-14 |
2005-02-01 |
Ixsys, Inc. |
Methods of optimizing antibody variable region binding affinity
|
|
CA2432978C
(en)
|
2000-12-22 |
2012-08-28 |
Medlyte, Inc. |
Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
|
|
CA2461212C
(en)
*
|
2001-09-27 |
2010-08-17 |
Kyorin Pharmaceutical Co., Ltd. |
Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
|
|
EP1481680A1
(en)
*
|
2003-05-30 |
2004-12-01 |
Aventis Pharma Deutschland GmbH |
Use of S1P
|
|
EP1484057A1
(en)
*
|
2003-06-06 |
2004-12-08 |
Aventis Pharma Deutschland GmbH |
Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
|
|
USRE43728E1
(en)
*
|
2003-11-21 |
2012-10-09 |
Actelion Pharmaceuticals Ltd. |
Thiazolidin-4-one derivatives
|
|
NZ549162A
(en)
*
|
2004-02-24 |
2009-12-24 |
Sankyo Co |
Amino-pyrrol alcohol compounds
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
US8324237B2
(en)
*
|
2005-05-20 |
2012-12-04 |
Smith Charles D |
Methods for the treatment and prevention of inflammatory diseases
|
|
JP2009526073A
(ja)
*
|
2006-02-09 |
2009-07-16 |
ユニバーシティ オブ バージニア パテント ファンデーション |
二環式スフィンゴシン−１−リン酸受容体アナログ
|
|
PL2087002T3
(pl)
*
|
2006-10-27 |
2015-02-27 |
Lpath Inc |
Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
|
|
US8563594B2
(en)
*
|
2007-05-08 |
2013-10-22 |
Allergan, Inc. |
S1P3 receptor inhibitors for treating pain
|
|
WO2009074969A2
(en)
*
|
2007-12-12 |
2009-06-18 |
University Of Lausanne |
Sphingosine-1-phosphate, analogs and antagonists for use as medicaments
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
EP2328863A1
(en)
*
|
2008-08-12 |
2011-06-08 |
Allergan, Inc. |
Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof
|